Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue 1, 1997, Pages 54-62

  Holtgrave, David R ^a   Pinkerton, Steven D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cost and cost benefit analysis; Economic evaluation of HIV AIDS; Quality of life

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL CARE; MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL; TREATMENT OUTCOME;

EID: 0030783238     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199709010-00009     Document Type: Review

References (31)

1. Holtgrave DR, Quails NL, Graham JD, Economic evaluation of HIV primary prevention. Annu Rev Public Health 1996;17:467-88.
2. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO, eds. Prevention effectiveness. New York: Oxford University Press, 1996.
3. Holtgrave DR, Setting priorities and community planning for HIV-prevention programs. AIDS Public Policy J 1994;9:145-51.
4. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Costeffectiveness in health and medicine. New York: Oxford University Press, 1996.
5. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Am J Public Health 1996;86:1442-5.
6. Guinan ME, Farnham PG, Holtgrave DR. Estimating the value of preventing a human immunodeficiency virus infection. Am J Prev Med 1994;10:1-4.
7. Holtgrave DR, Quails NL. Threshold analysis and HIV prevention programs. Med Decis Making 1995;15:311-7.
8. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
9. Voelker R. Can researchers use new drugs to push HIV envelope to extinction? JAMA 1996;276:435-7.
10. Ho, DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333:450-1.
11. Richman DD, HIV therapeutics. Science 1996;272:1886-7.
12. Anonymous. New drugs for HIV infection. Medical Letter on Drugs and Therapeutics. 1996;38:35-7.
13. Mellors JW, Kingsley JA, Rinaldo CR Jr, et al. Quantitation of HIV-I RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
14. Decks G, Smith M, Holodnly M, Kahn JO. HIV-I protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
15. American Health Consultants. Panels to develop standards for antiviral therapy, viral-load testing. AIDS Alert 1997;12:13-5.
16. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993;270:474-8.
17. U.S. Bureau of Labor Statistics. Consumer price index tables. World Wide Web site, http://stats.bls.gov:80/cgi_bin/surveymost, August 13 1996 (data also available from first author).
18. Tsevat J, Solzan JG, Kuntz KM, et al. Health values of patients with human immunodeficiency virus: relationship to mental health and physical functioning. Med Care 1996;34:44-57.
19. Wu AW, Mathews WC, Brysk LT, et al. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1990;3:683-90.
20. Revicki DA, Wu AW, Murray MI. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care 1995;33(Suppl):AS173-AS182.
21. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Med Care 1991;29:786-98.
22. Schag CAC, Ganz PA, Kahn B, Petersen L. Assessing the needs and quality of life of patients with HIV infection: development of the HIV Overview of Problems Evaluation System (HOPES). Qual Life Res 1992;1:397-413.
23. Owens DK, Nease RF Jr. Transmission of HIV infection between provider and patient: a quantitative analysis of risk. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS epidemic: planning, policy, and prediction. New York: Raven Press, 1994:153-77.
24. Holzerner WL, Wilson HS, Quality of life and the spectrum of HIV infection. Annu Rev Nurs 1995;13:3-29.
25. Patrick DL, Erikson P. Health status and health policy: allocating resources to health care. New York: Oxford University Press, 1993.
26. + counts disease stages based on treatment protocols, J Acquir Immune Defic Syndr Hum Retrovirol 1996;12: 413-20.
27. American Health Consultants. Viral-load testing may lower high cost of therapy. AIDS Alert 1996;11:100-1.
28. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J 1993;148:927-9.
29. Owens DK, Nease RF, Harris R. Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings [abstract]. Med Decis Making 1993;13: 395.
30. Tolley GL, Kenkel D, Fabian R, eds. Valuing health for policy: an economic approach. Chicago: University of Chicago Press. 1994.
31. Pinkerton SD, Holtgrave DR. Lifetime costs of HIV/AIDS medical care [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:380-2.